Cover Image
市場調查報告書

胰島素注射液的全球市場:2015年∼2019年

Global Human Insulin Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 247841
出版日期 內容資訊 英文 63 Pages
訂單完成後即時交付
價格
Back to Top
胰島素注射液的全球市場:2015年∼2019年 Global Human Insulin Market 2015-2019
出版日期: 2015年08月12日 內容資訊: 英文 63 Pages
簡介

全球胰島素注射液市場預測在2014年∼2019年這段期間將以年複合成長率(CAGR)10.29%的速度成長。

本報告提供全球胰島素注射液市場相關調查分析,提供您市場規模與成長率,市場趨勢,市場的推動要素與課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

第1章 摘要整理

  • 焦點

第2章 調查範圍

  • 市場概要
  • 主要供應商的產品

第3章 產品簡介

第4章 市場調查手法

  • 調查手法
  • 經濟指標

第5章 疾病概要

  • 流行病學

第6章 開發平台分析

第7章 簡介

第8章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第9章 市場區隔:胰島素類別

  • 速效性
  • 中長效期
  • 長效期

第10章 市場區隔:疾病類別

第11章 地區部門

第12章 推動市場成長要素

第13章 成長推動因素的影響

第14章 市場課題

第15章 推動因素與課題的影響

第16章 市場趨勢

第17章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • 其他卓越供應商

第18章 主要供應商分析

  • Lilly
  • Novo Nordisk
  • Sanofi

第19章 附錄

  • 簡稱清單

第20章 關於Technavio

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR6990

About diabetes

Insulin is a hormone produced by beta cells of the pancreas that plays a key role in the regulation of blood glucose levels. It controls the body systems and regulates the uptake of amino acids by body cells. It helps cells absorb glucose from the blood. In diabetics, cells stop responding to the insulin produced. As a result, glucose in the blood cannot be absorbed by the cells of the body. This condition damages body tissues over the period of time and causes disabling and life-threatening health complications such as diabetic nephropathy and diabetic retinopathy. In type 1 diabetes, the body does not produces sufficient insulin to regulate blood glucose level. Individuals with this type of diabetes need to take insulin daily. Patients with type 2 diabetes also need doses of insulin coupled with medication. Different types of insulin such as human insulin and insulin analogs are available as insulin replacement therapy.

Technavio's analysts forecast the global human insulin market to grow at a CAGR of 10.29% over the period 2014-2019.

Covered in this report

The report includes the present scenario and the growth prospects of the global human insulin market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of diabetes.

Technavio's report, Global Human Insulin Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report includes a discussion of the key vendors operating in this market.

Key vendors

  • Eli Lilly
  • Novo Nordisk
  • Sanofi

Other Prominent Vendors

  • Biocon
  • Biodel
  • Biogenomics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Diamyd Medical
  • Diasome Pharmaceuticals
  • DiaVacs
  • Pfizer
  • Generex Biotechnology
  • Lexicon Pharmaceuticals
  • Macrogenics
  • Merck
  • Oramed Pharmaceuticals
  • Osiris Therapeutics
  • Thermalin Diabetes
  • Tolerion
  • Wockhardt
  • XOMA Corporation

Market driver

  • Increase in prevalence of diabetes
  • For a full, detailed list, view our report

Market challenge

  • Stringent regulatory environment
  • For a full, detailed list, view our report

Market trend

  • Increasing R&D for novel mechanisms
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Product profiles

PART 04: Market research methodology

  • Research methodology
  • Economic indicators

PART 05: Disease overview

  • Epidemiology

PART 06: Pipeline analysis

PART 07: Introduction

  • Key market highlights

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by type of insulin

  • Fast-acting insulin
  • Intermediate-acting insulin
  • Long-acting insulin

PART 10: Market segmentation by type of disease

PART 11: Geographical segmentation

PART 12: Market drivers

PART 13: Impact of drivers

PART 14: Market challenges

PART 15: Impact of drivers and challenges

PART 16: Market trends

PART 17: Vendor landscape

  • Competitive scenario
  • Market share analysis 2014
  • Other prominent vendors

PART 18: Key vendor analysis

  • Lilly
  • Novo Nordisk
  • Sanofi

PART 19: Appendix

  • List of abbreviation

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Diabetes prevalence rate in various countries (2000 and 2030)
  • Exhibit 03: Global human insulin market 2014-2019 ($ Billions)
  • Exhibit 04: Five forces analysis
  • Exhibit 05: Global human insulin market by type of disease 2014
  • Exhibit 07: Global human insulin market segmentation by geography 2014
  • Exhibit 08: Impact of drivers
  • Exhibit 09: Impact of drivers and challenges
  • Exhibit 10: Novo Nordisk: Company strategy
  • Exhibit 11: Modern insulins: Drug sales 2010-2014 ($ millions)
  • Exhibit 12: NovoRapid/NovoLog: Drug sales 2010-2014 ($ millions)
  • Exhibit 13: Levemir: Drug sales 2010-2014 ($ millions)
  • Exhibit 14: NovoMix: Drug sales 2010-2014 ($ millions)
  • Exhibit 15: Human insulins: Drug sales 2010-2014 ($ millions)
  • Exhibit 16: Sanofi: Company strategy
  • Exhibit 17: Lantus: Drug sales 2010-2014 ($ millions)
  • Exhibit 18: Apidra: Drug sales 2010-2014 ($ millions)
  • Exhibit 19: Insuman: Drug sales 2010-2014 ($ millions)
  • Exhibit 20: Lilly: Company strategy
  • Exhibit 21: Humalog: Drug sales 2010-2014 ($ millions)
  • Exhibit 22: Humulin: Drug sales 2010-2014 ($ millions)
  • Exhibit 23: Novo Nordisk: R&D expenditure 2014
Back to Top